The tracker is simple enough to keep using, and the daily targets stay visible enough to matter over time
On April 1, the FDA approved Foundayo (orforglipron), Eli Lillys once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002
If we trace the revenue from the manufacturer down to the patient, we see a stark contrast between the current global monopoly model and the impending Indian generic reality
It has the advantages of a prolonged administration interval (once a week), few adverse reactions in the digestive tract (122), and adverse effects reported ranging from mild to moderate (122, 123)
ADHD symptoms are likely at an all-time low, and you are probably more able to focus, remain resilient through struggle and frustration, and manage rejection or setbacks during this time
The enthusiasm that comes with rapid progress sometimes leads to overexertion